Contribute Try STAT+ Today

Nathaniel “Ned” David, the co-founder and president of Unity Biotechnology (UBX), is one of biotech’s big idea guys. Before starting Unity in 2011, David founded four other companies that raised $1.5 billion in financing and now employ 400 people. The idea behind Unity is particularly vast: The company is targeting the science around aging, and all the diseases that can result from it.

Its first studies, due to read out over the next few years, are in arthritis and eye diseases like glaucoma and age-related macular degeneration. The goal, David says, is not to extend life, but to increase “healthspan,” the length of time during which people are healthy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Very interesting to read, thanks! Could you share the paper that is mentioned as well? Thanks!

Comments are closed.